BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

An inhibitor of the ALOX12-ACACA interaction for NASH

By Claire Quang, Staff Writer
February 11, 2022 9:00 PM UTC

DISEASE CATEGORY: Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH)...

BCIQ Company Profiles

Wuhan University

BCIQ Target Profiles

Acetyl-Coenzyme A carboxylase alpha (ACACA) (ACC1)

Arachidonate 12-lipoxygenase (ALOX12) (12-LOX)

BCIQ Company Profiles

Wuhan University

BCIQ Target Profiles

Acetyl-Coenzyme A carboxylase alpha (ACACA) (ACC1)

Arachidonate 12-lipoxygenase (ALOX12) (12-LOX)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2026 BioCentury Inc. All Rights Reserved.
Copyright © 2026 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS